EyeGene Inc (185490)

Currency in KRW
1,411
+33(+2.39%)
Delayed Data·
185490 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,3401,470
52 wk Range
1,1823,905
Key Statistics
Bid/Ask
1,411.00 / 1,417.00
Prev. Close
1,378
Open
1,340
Day's Range
1,340-1,470
52 wk Range
1,182-3,905
Volume
83.74K
Average Volume (3m)
1.61M
1-Year Change
-54.6795%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
185490 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 15, 2026
EPS / Forecast
-79.85 / --
Revenue / Forecast
1.27B / --
EPS Revisions
Last 90 days

185490 Income Statement

Compare 185490 to Peers and Sector

Metrics to compare
185490
Peers
Sector
Relationship
P/E Ratio
−3.7x−10.7x−0.4x
PEG Ratio
0.27−0.250.00
Price/Book
1.1x1.6x2.6x
Price / LTM Sales
14.8x6.7x3.1x
Upside (Analyst Target)
-251.7%48.3%
Fair Value Upside
Unlock16.1%6.1%Unlock

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
10.01M23.16%13.35B
Public Companies & Retail Investors
33.22M76.84%44.28B
Total
43.23M100.00%57.63B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BMI Korea Co., Ltd.23.16%10,013,22113,347,624

People Also Watch

9,040
001740
-0.22%
2,480
001510
-4.06%
18,880
214320
+0.27%
73,800
064400
-0.27%

FAQ

What Is the EyeGene (185490) Stock Price Today?

The EyeGene stock price today is 1,411 KRW.

What Stock Exchange Does EyeGene Trade On?

EyeGene is listed and trades on the KOSDAQ.

What Is the Stock Symbol for EyeGene?

The stock symbol for EyeGene is "185490."

What Is the EyeGene Market Cap?

As of today, EyeGene market cap is 59.57B KRW.

What Is EyeGene's Earnings Per Share (TTM)?

The EyeGene EPS (TTM) is -506.

From a Technical Analysis Perspective, Is 185490 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has EyeGene Stock Split?

EyeGene has split 2 times.

What is the current trading status of EyeGene (185490)?

As of Jul 07, 2026, EyeGene (185490) is trading at a price of 1,411 KRW, with a previous close of 1,378 KRW. The stock has fluctuated within a day range of 1,340 KRW to 1,470 KRW, while its 52-week range spans from 1,182 KRW to 3,905 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.